脾多肽注射液联合利奈唑胺治疗革兰阳性菌感染重症肺炎患者的临床疗效

Clinical Efficacy of Spleen Polypeptide Injection Combined with Linezolid in the Treatment of Patients with Severe Pneumonia Infected by Gram-positive Bacteria

目的:探讨脾多肽注射液联合利奈唑胺治疗革兰阳性菌感染重症肺炎的临床效果。方法:选取本院2017年1月~2019年1月收治的84例革兰阳性菌感染重症肺炎患者,采用随机数字表法分为对照组和观察组,每组42例。对照组在常规治疗基础上给予利奈唑胺治疗,观察组在常规治疗基础上给予脾多肽注射液联合利奈唑胺治疗。对比两组患者临床疗效、治疗前后T细胞亚群水平及不良反应发生率。结果:两组患者临床疗效比较具有统计学差异(P<0.05),且观察组总有效率(100.00%)高于对照组(88.10%);治疗前两组患者CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+)水平比较无统计学差异(P>0.05);与治疗前相比,两组患者CD4^(+)和CD4^(+)/CD8^(+)水平均升高,CD8^(+)水平均降低(P<0.05);且观察组CD4^(+)和CD4^(+)/CD8^(+)水平高于对照组(P<0.05);CD8+水平低于对照组(P<0.05);观察组不良反应总发生率(11.90%)高于对照组(7.14%),无统计学差异(P>0.05)。结论:脾多肽注射液联合利奈唑胺能增强革兰阳性菌感染重症肺炎患者的疗效,可调节T细胞免疫指标水平,且安全可靠。

Objective: To investigate the clinical efficacy of spleen polypeptide injection combined with linezolid in the treatment of severe pneumonia caused by Gram-positive bacteria. Methods: A total of 84patients with severe pneumonia infected by Gram-positive bacteria admitted in our hospital from January 2017 to January 2019 were selected as research subjects and randomly divided into the control group and the observation group by random number table method, with 42 cases in each group. The control group was treated with linezolid on the basis of routine treatment, and the observation group was treated with spleen polypeptide injection combined with linezolid on the basis of routine treatment. The recovery time of clinical efficacy, the level of T cell subsets and the incidence of adverse reactions were compared between the two groups. Results: There were significant differences in the clinical efficacy between the two groups(P<0.05),and the total effective rate of the observation group(100.00%) was higher than that of the control group(88.10%). There was no significant difference in the levels of CD4^(+), CD8^(+)and CD4^(+)/CD8^(+)between the two groups before treatment(P>0.05). Compared with those before treatment, the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups increased and the level of CD8^(+)decreased(P<0.05). The levels of CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05), and the level of CD8^(+)in the observation group was lower than that in the control group(P<0.05). The total incidence of adverse reactions in the observation group(11.90%) was higher than that in the control group(7.14%) with no significant difference(P>0.05). Conclusion: Spleen polypeptide injection combined with linezolid can enhance the therapeutic effect in patients with severe pneumonia infected by Gram-positive bacteria and regulate the level of T cell immune indexes. It is safe and reliable.